Modern approaches to interpretation of clinical trial results to evaluate the effectiveness of heart failure therapy. Analysis of the results of randomized trials PARADIGM-HF, DAPA-HF, EMPEROR-Reduced and VICTORIA
https://doi.org/10.15829/1560-4071-2023-5422
Abstract
The article discusses the results of modern studies evaluating the effectiveness of drug therapy for heart failure with reduced ejection fraction (HFrEF). Modern approaches to a comprehensive evaluation of data obtained in various randomized clinical trials (RCTs) are presented. The role of methods for presenting the RCT results is considered, as well as the difference between hazard ratio and relative risk is clarified. Expert opinions are discussed about the limitations of simplified approaches to comparing the results of large RCTs, which are based only on comparisons of hazard ratio without taking consideration of patient characteristics, study duration, and the absolute number of adverse outcomes that developed. Information is provided on the role of accounting for multiple comparisons in assessing clinical outcomes in RCTs. The article compares the VICTORIA results on the study of vericiguat in patients with a recent episode of HFrEF decompensation with RCTs on the evaluation of the effects of drugs that are part of standard therapy.
About the Authors
S. R. Gilyarevsky
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Moscow
Yu. V. Mareev
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
Moscow
References
1. Bhatt AS, Abraham WT, Lindenfeld J, et al. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. JACC Heart Fail. 2021;9(1):1-12. doi:10.1016/j.jchf.2020.10.014.
2. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547-52. doi:10.1056/NEJM198606123142404.
3. Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. doi:10.1056/NEJM199108013250501.
4. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. doi:10.1056/NEJM198706043162301.
5. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-55. doi:10.1056/NEJM199605233342101.
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. doi:10.1016/S0140-6736(98)11181-9.
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. doi:10.1016/S0140-6736(99)04440-2.
8. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. doi:10.1056/NEJM199909023411001.
9. Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492.
10. Taylor AL, Ziesche S, Yancy C, et al.; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57. doi:10.1056/NEJMoa042934.
11. Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. doi:10.1016/S0140-6736(10)61198-1.
12. McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.
13. Greene SJ, Fonarow GC, Butler J. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. Circ Heart Fail. 2020;13(6):e007132. doi:10.1161/CIRCHEARTFAILURE.120.007132.
14. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-29. doi:10.1016/S0140-6736(20)31824-9.
15. Armstrong PW, Pieske B, Anstrom KJ, et al.; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-93. doi:10.1056/NEJMoa1915928.
16. Teerlink JR, Diaz R, Felker GM, et al.; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021;384(2):105-16. doi:10.1056/NEJMoa2025797.
17. DeVore AD, Hill CL, Thomas L, et al. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. Circ Heart Fail. 2018;11(9):e005400. doi:10.1161/CIRCHEARTFAILURE.118.005400.
18. Butler J, Anstrom KJ, Armstrong PW. Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. Circulation. 2020;142(8):717-19. doi:10.1161/CIRCULATIONAHA.120.047086.
19. Sedgwick P. Hazards and hazard ratios. BMJ. 2012;345. doi:10.1136/bmj.e5980.
20. Sedgwick P, Joekes K. Interpreting hazard ratios. BMJ. 2015;351:h4631. doi:10.1136/bmj.h4631.
21. Sutradhar R, Austin PC. Relative rates not relative risks: addressing a widespread misinterpretation of hazard ratios. Ann Epidemiol. 2018;28(1):54-7. doi:10.1016/j.annepidem.2017.10.014.
22. Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72(1):215-21. doi:10.1111/biom.12384.
23. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.
24. Mann DL, Givertz MM, Vader JM, et al.; LIFE Investigators. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):17-25. doi:10.1001/jamacardio.2021.4567.
25. Schwartz GG, Steg PG, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107. doi:10.1056/NEJMoa1801174.
26. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313-24. doi:10.1002/sim.1201.
27. Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovas-cular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413-24. doi:10.1056/NEJMoa2022190.
Review
For citations:
Gilyarevsky S.R., Mareev Yu.V. Modern approaches to interpretation of clinical trial results to evaluate the effectiveness of heart failure therapy. Analysis of the results of randomized trials PARADIGM-HF, DAPA-HF, EMPEROR-Reduced and VICTORIA. Russian Journal of Cardiology. 2023;28(5):5422. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5422
Views:
1090
Email this article 